.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Deloitte
Argus Health
UBS
QuintilesIMS
Federal Trade Commission
Mallinckrodt
Cantor Fitzgerald
Farmers Insurance
Cerilliant

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,791,122

« Back to Dashboard

Which drugs does patent 8,791,122 protect, and when does it expire?


Patent 8,791,122 protects UPTRAVI and is included in one NDA.

This patent has twenty-six patent family members in twenty countries.

Summary for Patent: 8,791,122

Title:Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl)acetamide and method for producing the same
Abstract: A main object of the present invention is to provide a novel crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl)acetamide (hereinafter referred to as "compound A"). A Form-I crystal of compound A shows diffraction peaks at 9.4 degrees, 9.8 degrees, 17.2 degrees and 19.4 degrees in the powder X-ray diffraction spectrum thereof. A Form-II crystal of compound A shows diffraction peaks at 9.0 degrees, 12.9 degrees, 20.7 degrees and 22.6 degrees in the powder X-ray diffraction spectrum thereof. A Form-III crystal of compound A shows diffraction peaks at 9.3 degrees, 9.7 degrees, 16.8 degrees, 20.6 degrees and 23.5 degrees in the powder X-ray diffraction spectrum thereof.
Inventor(s): Itou; Hideyuki (Kyoto, JP)
Assignee: Nippon Shinyaku Co., Ltd. (Kyoto, JP)
Application Number:13/379,531
Patent Claim Types:
see list of patent claims
Compound; Composition; Use; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Actelion Pharms LtdUPTRAVIselexipagTABLET;ORAL207947-001Dec 21, 2015RXYesNo► Subscribe► SubscribeYY► Subscribe
Actelion Pharms LtdUPTRAVIselexipagTABLET;ORAL207947-002Dec 21, 2015RXYesNo► Subscribe► SubscribeYY► Subscribe
Actelion Pharms LtdUPTRAVIselexipagTABLET;ORAL207947-003Dec 21, 2015RXYesNo► Subscribe► SubscribeYY► Subscribe
Actelion Pharms LtdUPTRAVIselexipagTABLET;ORAL207947-004Dec 21, 2015RXYesNo► Subscribe► SubscribeYY► Subscribe
Actelion Pharms LtdUPTRAVIselexipagTABLET;ORAL207947-005Dec 21, 2015RXYesNo► Subscribe► SubscribeYY► Subscribe
Actelion Pharms LtdUPTRAVIselexipagTABLET;ORAL207947-006Dec 21, 2015RXYesNo► Subscribe► SubscribeYY► Subscribe
Actelion Pharms LtdUPTRAVIselexipagTABLET;ORAL207947-007Dec 21, 2015RXYesNo► Subscribe► SubscribeYY► Subscribe
Actelion Pharms LtdUPTRAVIselexipagTABLET;ORAL207947-008Dec 21, 2015RXYesYes► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,791,122

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2009-151727Jun 26, 2009
Japan2009-151728Jun 26, 2009
Japan2009-151729Jun 26, 2009
PCT Information
PCT FiledJune 25, 2010PCT Application Number:PCT/JP2010/060798
PCT Publication Date:December 29, 2010PCT Publication Number: WO2010/150865

Non-Orange Book Patents for Patent: 8,791,122

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,284,280Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl)acetamide► Subscribe
9,440,931Form-III crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl)acetamide and use thereof► Subscribe
9,340,516Form-II crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl) acetamide, method for producing the same, and use thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,791,122

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina077242► Subscribe
Australia2010263569► Subscribe
BrazilPI1015936► Subscribe
Canada2764475► Subscribe
China102459198► Subscribe
China104326991► Subscribe
Colombia6430432► Subscribe
European Patent Office2447254► Subscribe
Israel216928► Subscribe
JapanWO2010150865► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Chinese Patent Office
McKesson
McKinsey
Accenture
Chubb
Farmers Insurance
Baxter
Johnson and Johnson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot